Coya Therapeutics, Inc. Stock Price, News & Analysis

Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, announces its participation in the H.C. Wainwright 3rd Annual BioConnect Conference on May 20, 2025. CEO Arun Swaminathan will engage in a fireside chat at 12:30pm ET at the Nasdaq World Headquarters in New York City.

The presentation will be available via webcast, with management offering one-on-one meeting opportunities. The webcast will be accessible through Coya's website and remain available for 90 days after the event.

Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, has announced its participation in two upcoming conferences in May 2025. The company's leadership, including CEO Dr. Arun Swaminathan and CFO David Snyder, will be available for one-on-one meetings with registered investors at:

1. The D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York

2. The Mizuho Neuro & Opthalmology Summit from May 20-21, 2025, at the Park Lane Hotel in New York

Coya Therapeutics (NASDAQ: COYA) has announced positive interim results from an investigator-initiated open-label study testing low-dose IL-2 and CTLA4-Ig combination treatment in Frontotemporal Dementia (FTD) patients. The study, conducted at Houston Methodist Neurological Institute, showed promising results in the first cohort of 5 patients.

Key findings include:

• Statistically significant increase in Treg numbers and suppressive function
• Minimal to no cognitive decline throughout the study period
• Well-tolerated treatment with no serious adverse events
• All 5 patients completed the 22-week treatment course

This is particularly notable as FTD patients typically experience rapid cognitive decline, with historical data showing an average 3.57-point worsening over 12 months on the CDR-FTLD scale. The treatment's success in maintaining cognitive function suggests potential therapeutic value for FTD, which currently has no approved treatments.

Coya Therapeutics (NASDAQ: COYA) has published research results for COYA 303, a novel biologic combination of low-dose interleukin 2 (LD IL-2) and GLP-1 receptor agonist (GLP-1RA), designed to enhance regulatory T cell (Treg) function in autoimmune and neurodegenerative diseases.

The study, conducted at Houston Methodist Research Institute, demonstrated that COYA 303 achieved a 42% increase in Treg suppressive function, significantly outperforming individual components (LD IL-2 at 15% and GLP-1RA at 20%). The combination therapy also showed enhanced Treg survival through reduced BAX transcript levels and inhibition of Treg apoptosis.

The research suggests COYA 303 could offer a differentiated approach for conditions like Alzheimer's Disease, where GLP-1 RAs have shown promise, by combining anti-inflammatory effects with enhanced Treg survival and function.

Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company focused on regulatory T cell (Treg) function enhancement, has announced an upcoming presentation at the ADPD 2025 conference in Vienna.

Principal Investigator Dr. Alireza Faridar from Houston Methodist Hospital will present progress updates on a Phase II clinical trial investigating low-dose IL-2 treatment in patients with mild to moderate Alzheimer's disease. The presentation is scheduled for April 5, 2025.

Coya Therapeutics (NASDAQ: COYA) provided an update on its Treg-derived exosome platform development for treating systemic and neurodegenerative diseases. The company's research has shown that regulatory T cell-derived exosomes (Treg exosomes) effectively suppress inflammation in preclinical models.

Key developments include:

• Treg exosomes demonstrated strong therapeutic potential in suppressing inflammation in neurodegenerative disease models
• Initial engineering batches using healthy donor Tregs planned for Q1 2025
• GMP manufacturing of larger-scale clinical batches scheduled for Q4 2025
• Program funded by Johnson Center for Cellular Therapeutics, Hop On A Cure, and Energy Transfer

The company highlighted that Treg exosomes have advantages over Tregs as they target myeloid cells driving disease progression and resist conversion to non-suppressive phenotypes in inflammatory environments.

Coya Therapeutics (NASDAQ: COYA) has reported its fiscal 2024 results and corporate updates. The company ended 2024 with $38.3 million in cash and reported a net loss of $14.9 million, compared to $8.0 million in 2023.

Key financial achievements include raising $10.0M through private placement, receiving a $5.0M strategic investment from the Alzheimer's Drug Discovery Foundation, and securing $3.85M from Dr. Reddy's Laboratories.

R&D expenses increased to $11.9 million in 2024 from $5.5 million in 2023, while G&A expenses rose to $8.9 million from $7.8 million.

The company announced positive results from Phase 2 studies in Alzheimer's disease and progress in Frontotemporal Dementia trials. Key upcoming catalysts for 2025 include submission of COYA-302 Phase 2 trial data for ALS treatment, potential milestone payments of $8.4M, and various data publications across their pipeline.

Coya Therapeutics (NASDAQ: COYA) announced that CEO Arun Swaminathan and Dr. Stanley H. Appel will participate in a BTIG-hosted KOL webcast titled "Is Alzheimer's next for GLP-1s and Combos?" on February 27, 2025. The discussion, moderated by Juliette Lafille of BTIG, will explore the potential of GLP-1 agonists and combination therapies for treating Alzheimer's disease.

Key topics will include:

• Potential for GLP-1s to slow cognitive decline in Alzheimer's
• Effects on brain metabolism and neuroinflammation reduction
• Efficacy through combinations
• Future development pathways

Coya recently expanded its pipeline with COYA 303, an investigational biologic combining COYA 301 (proprietary low-dose interleukin-2) with a GLP-1 receptor agonist designed for subcutaneous administration to treat inflammatory diseases.